Orexigen Therapeutics, Inc. Revises Obesity Drug, Contrave Data

Reuters -- Orexigen Therapeutics Inc said on Tuesday that fewer patients achieved key weight loss goals when taking its experimental obesity drug than originally reported, sending the company's stock down 11 percent.